
Cantel Medical Corp. Net Income 2011-2025 | CMD
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Cantel Medical Corp.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 13.7 M | 55 M | 91 M | 71.4 M | 60 M | 48 M | 43.3 M | 39.2 M | 31.3 M | 20.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 91 M | 13.7 M | 47.3 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical instruments industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Baxter International
BAX
|
-512 M | $ 19.11 | 0.95 % | $ 9.75 B | ||
|
Becton, Dickinson and Company
BDX
|
1.68 B | $ 196.12 | 0.23 % | $ 56.4 B | ||
|
Ekso Bionics Holdings
EKSO
|
-11.3 M | $ 5.47 | 3.01 % | $ 110 M | ||
|
Luminex Corporation
LMNX
|
15.2 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
-17.6 M | - | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
56.2 M | - | - | $ 955 M | ||
|
CRH Medical Corporation
CRHM
|
-24.5 M | - | - | $ 282 M | ||
|
iRhythm Technologies
IRTC
|
-113 M | $ 175.8 | -1.49 % | $ 5.48 B | ||
|
Isoray
ISR
|
-79.3 M | - | 0.03 % | $ 108 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
223 M | - | -0.05 % | $ 10.3 B | ||
|
Repro Med Systems
KRMD
|
-13.7 M | $ 6.48 | -0.61 % | $ 295 M | ||
|
Harvard Bioscience
HBIO
|
-3.42 M | $ 0.73 | 0.64 % | $ 31 M | ||
|
LeMaitre Vascular
LMAT
|
44 M | $ 84.34 | 0.44 % | $ 1.89 B | ||
|
Varian Medical Systems, Inc.
VAR
|
292 M | - | -0.02 % | $ 16.3 B | ||
|
ICU Medical
ICUI
|
-118 M | $ 146.98 | -0.35 % | $ 3.58 B | ||
|
Alcon
ALC
|
376 M | $ 80.17 | 0.06 % | $ 40.4 B | ||
|
Merit Medical Systems
MMSI
|
120 M | $ 87.39 | -0.27 % | $ 5.09 B | ||
|
AtriCure
ATRC
|
-44.7 M | $ 40.55 | 0.02 % | $ 1.9 B | ||
|
Atrion Corporation
ATRI
|
19.4 M | - | - | $ 810 M | ||
|
electroCore
ECOR
|
-18.8 M | $ 4.86 | 1.25 % | $ 26.8 K | ||
|
AngioDynamics
ANGO
|
-34 M | $ 13.16 | - | $ 538 M | ||
|
The Cooper Companies
COO
|
375 M | $ 82.57 | -0.37 % | $ 16.4 B | ||
|
Glaukos Corporation
GKOS
|
-135 M | $ 116.64 | 0.4 % | $ 5.65 B | ||
|
Masimo Corporation
MASI
|
-305 M | $ 133.28 | -0.44 % | $ 7.1 B | ||
|
Haemonetics Corporation
HAE
|
168 M | $ 80.01 | -0.44 % | $ 4.03 B | ||
|
InfuSystem Holdings
INFU
|
18 K | $ 9.11 | 0.77 % | $ 188 M | ||
|
Predictive Oncology
POAI
|
-12.7 M | - | - | $ 32.4 M | ||
|
Intuitive Surgical
ISRG
|
2.32 B | $ 577.15 | -0.03 % | $ 205 B | ||
|
OraSure Technologies
OSUR
|
-19.5 M | $ 2.43 | 2.53 % | $ 181 M | ||
|
Microbot Medical
MBOT
|
-10.7 M | $ 2.18 | - | $ 22.2 M | ||
|
Milestone Scientific
MLSS
|
-4.71 M | $ 0.29 | -0.48 % | $ 23.1 M | ||
|
Nephros
NEPH
|
-1.58 M | $ 5.23 | 12.23 % | $ 54.3 M | ||
|
NeuroMetrix
NURO
|
-7.81 M | - | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
-1.12 B | $ 22.0 | 0.59 % | $ 3.79 B | ||
|
Stereotaxis
STXS
|
-20.7 M | $ 2.43 | -0.82 % | $ 196 M | ||
|
Pro-Dex
PDEX
|
8.98 M | $ 40.4 | -2.38 % | $ 133 M | ||
|
Pulse Biosciences
PLSE
|
-42.2 M | $ 14.86 | 1.92 % | $ 714 M | ||
|
ResMed
RMD
|
779 M | $ 244.44 | -0.07 % | $ 35.7 B | ||
|
Repligen Corporation
RGEN
|
35.6 M | $ 165.66 | -0.42 % | $ 9.23 M | ||
|
BioLife Solutions
BLFS
|
-20.2 M | $ 25.41 | -0.2 % | $ 1.17 B | ||
|
STAAR Surgical Company
STAA
|
-20.2 M | $ 23.63 | -1.25 % | $ 1.16 B | ||
|
STERIS plc
STE
|
615 M | $ 255.68 | 0.11 % | $ 25.2 B | ||
|
Retractable Technologies
RVP
|
-11.9 M | $ 0.82 | 0.01 % | $ 24.5 M | ||
|
Teleflex Incorporated
TFX
|
69.7 M | $ 122.33 | 0.03 % | $ 5.73 B | ||
|
Utah Medical Products
UTMD
|
4.29 M | $ 56.29 | -1.14 % | $ 204 M | ||
|
DENTSPLY SIRONA
XRAY
|
-910 M | $ 11.22 | 1.26 % | $ 2.28 B | ||
|
West Pharmaceutical Services
WST
|
493 M | $ 276.66 | -0.3 % | $ 20.2 B |